Alertgy empowers diabetics with wearable wristband device

Via the Rochester Business Journal

Marc Rippen
Marc Rippen, Co-Founder and CEO of Alertgy

Alertgy is one of 10 startups from around the world working with the Luminate NY accelerator at NextCorps in downtown Rochester. These companies are helping to write the next chapter in Rochester’s history as the world’s center for optics, photonics, and imaging (OPI).

Each company in Luminate’s cohort 5 received an initial investment of $100,000 and is participating in the six-month program, which helps the companies speed the commercialization of their technologies and businesses. On October 19, at Finals 2022 at the Rochester Riverside Convention Center, they will compete for up to $2 million in follow-on investment. Funding for the $25 million program is being provided through Empire State Development’s Finger Lakes Forward Upstate Revitalization Initiative.

“The startups in our cohort are revolutionizing their fields by applying advances in optics, photonics, and imaging to technologies that will solve significant problems,” said Dr. Sujatha Ramanujan, managing director of Luminate. ”Alertgy is doing their part to make healthcare practices more accessible to people by developing a wearable device that empowers people to better manage their health–starting with diabetes care.”

We caught up with Marc Rippen, Alertgy’s CEO, to hear about how the company is working hard to help diabetics monitor their blood glucose levels and how that same technology can be used to help many others.

Tell us about your company.

Alertgy is changing the way diabetics manage type 2 diabetes, applying leading-edge technologies to non-invasively and continuously detect blood sugar levels through a wearable wristband and a smartphone app.

We are now in the process of designing the wristband for commercial use. We aim to also develop other applications for the device that will provide insights that lead to the early detection and better management of cancer, Alzheimer’s disease, and heart disease.

Read the full story